Topics in spinal cord injury rehabilitation

Differences in Prescribing Diabetes Drugs for People With and Without Spinal Cord Injuries

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

The frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) use in individuals with spinal cord injury (SCI) remains unexamined.

  • GLP-1RAs are known to be effective for managing obesity.
  • The impact of SCI on obesity management strategies is not well understood.
  • Current literature lacks specific data on GLP-1RA usage among individuals with SCI.
  • Further investigation may be needed to explore the applicability of GLP-1RAs in this population.

Simplified

Related papers

Sep '25
Glucagon-like peptide-1 receptor drugs linked to lower death, heart, and mental health risks in people with psoriasis
top 5% journal
cited by 22 papers
journal article
Aug '25
Changes in prescribing patterns of drugs that activate the glucagon-like peptide 1 receptor
top 30% journal
cited by 58 papers
observational study
Oct '25
Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration
top 5% journal
cited by 8 papers
multicenter study
Nov '25
Links Between Glucagon-Like Peptide-1 Treatments and Long-Term Cough
top 10% journal
cited by 9 papers
journal article
Nov '25
Drugs activating glucagon-like peptide-1 receptors are linked to fewer abdominal aortic aneurysm problems
top 5% journal
cited by 4 papers
journal article
Oct '25
Use of New GLP-1 Medicines in US Patients With and Without Alcohol Use Disorder, 2016-2024
top 20% journal
cited by 3 papers
journal article
Feb '26
How men and women differ in using glucagon-like peptide-1 receptor drugs beyond blood sugar control in the United States
top 20% journal
cited by 1 paper
journal article
Aug '25
Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Eye Inflammation
top 5% journal
cited by 12 papers
multicenter study
Jul '24
Glucagon-Like Peptide 1 Receptor Agonists and Risk of 13 Obesity-Related Cancers in People with Type 2 Diabetes
top 2% journal
cited by 233 papers
research support, n.i.h., extramural
Sep '24
Lower risk of repeated acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity who have had acute pancreatitis before
top 20% journal
cited by 21 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #59
GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes
6 days ago7 studies
issue #58
A new triple receptor drug cut body weight by nearly 20% in 24 weeks
1 week ago7 studies
issue #57
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
2 weeks ago7 studies
issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
3 weeks ago7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
4 weeks ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
6 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
7 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
8 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief